论文信息 - Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - 字舞流文

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

J. Leonard | I. Flinn | S. Coutre | R. Furman | Yeonhee Kim | N. Wagner-Johnston | J. Sharman | J. Barrientos | S. Vos | T. Boyd | L. Holes | R. Dansey | R. Dubowy